Skip to main content
PLOS One logoLink to PLOS One
. 2022 Mar 8;17(3):e0262433. doi: 10.1371/journal.pone.0262433

Optimization of COVID-19 vaccination and the role of individuals with a high number of contacts: A model based approach

Tarcísio M Rocha Filho 1,2,*, José F F Mendes 3, Thiago B Murari 4, Aloísio S Nascimento Filho 4, Antônio J A Cordeiro 4,5, Walter M Ramalho 6, Fúlvio A Scorza 7, Antônio-Carlos G Almeida 8, Marcelo A Moret 4,9
Editor: M Shamim Kaiser10
PMCID: PMC8903293  PMID: 35259169

Abstract

We report strong evidence of the importance of contact hubs (or superspreaders) in mitigating the current COVID-19 pandemic. Contact hubs have a much larger number of contacts than the average in the population, and play a key role on the effectiveness of vaccination strategies. By using an age-structures compartmental SEIAHRV (Susceptible, Exposed, Infected symptomatic, Asymptomatic, Hospitalized, Recovered, Vaccinated) model, calibrated from available demographic and COVID-19 incidence, and considering separately those individuals with a much greater number of contacts than the average in the population, we show that carefully choosing who will compose the first group to be vaccinated can impact positively the total death toll and the demand for health services. This is even more relevant in countries with a lack of basic resources for proper vaccination and a significant reduction in social isolation. In order to demonstrate our approach we show the effect of hypothetical vaccination scenarios in two countries of very different scales and mitigation policies, Brazil and Portugal.

Introduction

The first cases of human transmission of SARS-CoV-2 were reported in Wuhan Province in China in December 2019 [1]. By January 2020, the spread became an epidemic and was declared a pandemic on March 11 by the World Health Organization [2]. Since then, the virus has spread over all countries in the world, with more than 208 million total cases and 4.3 million deaths [3]. The estimates for the basic reproduction number R0 and herd immunity are estimated in the range of 2.8–3.3 [4, 5] and 0.64–0.7 [6, 7], respectively. With an infection fatality rate of 0.657% [8] (that varies according to the age distribution in the population), the natural free evolution would imply a death toll too large to be even considered as a possibility, and would result in overcrowded medical facilities, and an even larger economic impact than the one endured up to the present time [811]. Besides that, the duration of disease-generated immunity is not yet well known, with the complicating factor that the free circulation of the SARS-CoV-2 has lead to new potentially dangerous mutations [12, 13]. As a consequence, the different vaccines developed up to the current date [14] are important tools for effectively mitigating the current COVID-19 pandemic. An efficient and properly designed immunization strategy would certainly result in the best payoffs, for the whole health system, for the population well-being, and resulting to something close to a fully working economy.

The World Health Organization COVAX initiative, a global vaccine alliance, aims to allocate two billion vaccine doses during 2021 across different participant countries [15], roughly a quarter of the world population. A total of 4.7 billion vaccine doses were administered in the world [3] to the current date for a total population of 7.8 billion, with a limited number of vaccine doses available, especially in poorer countries. As a consequence priorities were established for the vaccination order, mainly by age and healthcare personnel, workers in essential and critical industries, individuals at higher risk for severe COVID-19, and individuals of 65 years of age and older [16]. In the European Union elderly people, healthcare workers and individuals with certain comorbidities were the first in line [17]. In Brazil, third in number of cases and second in deaths among all countries, the vaccination just started with healthcare workers, 75 years of age and older individuals, long-term care facilities patients with 60 years of age and older, indigenous peoples living in reservations, and traditional communities in river banks, individuals with comorbidities, and now reaching younger adults [18].

A priority ranking becomes unavoidable as the selected priority groups may constitute a considerable fraction of the population. This may change with time as one expects the general guidelines to be modified as more evidence is gathered on the COVID-19 epidemiology and on the vaccine safety and efficacy for each target group. A survey carried out in Belgium asked 2060 participants aged 18 to 80 who should be vaccinated first, second and so on and reached no consensus [19], showing that the perception of such priorities in the whole population is not clear yet. A methodology to carefully analyze the current situation, considering the social contacts structure in a given population and its age distribution, is necessary in order to design the most efficient approach for the vaccination against COVID-19, in order to minimize deaths, hospitalizations and other negative impacts of the current pandemic.

The stage of the pandemic in each country must also be considered, as some vaccine variants may be more effective in reducing the likelihood of severe COVID-19 cases, while others may be effective in reducing transmission [7]. Besides, large-scale vaccination aimed at achieving herd immunity poses many logistic and social difficulties [20], with diverse rational designs [21, 22], and prioritization plans of vaccination determining the evolution of the COVID-19 pandemic. The willingness of the population to get vaccinated and the economic costs, considering that free vaccines are not always available in many countries, are also variables to acknowledge when designing and analyzing the impacts of vaccination campaigns [23, 24]. A successful and equitable vaccination strategy will obviously have to carefully consider each one of these points, and some fundamental ethical choices already agreed upon.

The aim of the present work is to use an epidemiological model, fitted from real past data, to discuss the effectiveness of different vaccination strategies, and particularly the role of individual with a significantly larger number of contacts in the spread of the virus, called here “superspreaders” (not to be confused with individuals with a higher virus shedding), as depicted in Fig 1. Possible superspreaders comprise teachers at all levels, public transport and supermarket workers dealing directly with the public, among other social network hubs. This type of population heterogeneity can have relevant effects on the spread of the pandemic and should be considered carefully when designing a vaccination strategy. Indeed, previous works on fictional communities arranged in free-scale networks show that the choice of who should be vaccinated first can greatly impact the evolution of an epidemic [2530].

Fig 1. Pictorial representation of contact hubs: Superspreaders (in red) have a much higher number of contacts than the average individuals (in black).

Fig 1

Arrows represent social contacts able to transmit the virus.

We do not intend to reproduce current vaccination strategies or predict future outcomes given the current situation, but to discuss different hypothetical scenarios and discuss how future vaccination campaigns can be optimized in light of the results presented here. We chose to analyze the cases of Brazil and Portugal. Besides being the countries of the authors and historically very connected, they were both heavily inflicted by the still on-going COVID-19 pandemic, have very different sizes and populations, and with quite different vaccination stages, with 20.3% and 64.75% of the population in Brazil and Portugal fully vaccinated, respectively [18, 31]. This allows for a more thorough comparison of the proposed scenarios with the known current situation in both countries. On the other hand, many other countries are still in a very early stage of vaccinating their populations, mainly in Africa, where many countries have fully vaccinated less than 2% of its whole population [32]. We hope that the results presented here will contribute to the future design of vaccination strategies.

Methods

Epidemiological model

We consider an age-stratified SEIAHRV model with homogeneous mixing and compartments for susceptible (S), exposed (E), symptomatic infected (I), asymptomatic infected (A), hospitalized (H), recovered (R), vaccinated without primary vaccination failure (V) and vaccinated with primary vaccination failure (U) individuals, as described in Table 1. The age groups considered are 0 to 9, 10 to 19, 20 to 29, 30 to 39, 40 to 49, 50 to 59, 60 to 69, 70 to 79 and 80 or more years of age. All variables in the model are proportions with respect to the initial population N0 (the current population changes due to mortality and birth). The flow chart for the model is given in Fig 2 and the corresponding differential equations in Eq. (S1) of the S1 File. All required parameters are given in [8, 3336] and are shown in S1-S3 Tables in S1 File.

Table 1. Variables in the epidemiological model.

All proportions are with respect to the initial population N0. The index i = 1, …, M denotes the age group (M = 9 in the present case).

Variable Description
S i Proportion of susceptible individuals
E i Proportion of exposed individual in the incubation period and not contagious.
I i Proportion of infected symptomatic individuals (contagious).
A i Proportion of infected asymptomatic individuals (contagious).
H i Proportion of hospitalized individuals.
R i Proportion of recovered individuals.
V i Proportion of vaccinated individuals without primary vaccination failure.
U i Proportion of vaccinated individuals with primary vaccination failure.
n i Proportion of the population in the i-th age group.

Fig 2. Epidemiological SEIAHRV model flow chart.

Fig 2

The continuous arrows represent rates between variables. The dotted lines indicate the proportion with respect to N0 of vaccine shots (see below). In the diagram μ′ ≡ μN/N0 and κ′ ≡ κN/N0, with μ and κ the natural death and birth rates in the population, respectively, and N the current total population. The proportion in the age group i with respect to N0 is denoted by ni and the aging rate νi from group i is given by the inverse of the time span of the age group in the time unit used. All parameters are given in S1-S3 Tables in S1 File.

The force of infection λi in Fig 2 for the i-the age group is given by

λi=j=1Mβi,j(Ij+ξAj)/ni, (1)

where βi,j are the components of the transmission matrix giving the probability per unit of time that a symptomatic infected individual (Ij) of age group j to infect a susceptible individual (Si) of age group i. For an asymptomatic individual (Aj) this probability is χβi,j. The transmission matrix is related to the contact matrix by the relation βi,j = pcCi,j where pc is the probability of contagion of a susceptible individual by an infectious symptomatic individual and supposed to be age-independent. The contact matrix varies with time due to social distancing and behavioral changes during the pandemic. We suppose here that such time variation can be represented by a single time-dependent factor ω(t) such that Ci,j(t) = ω(t)Ci,j(0), with Ci,j(0) the components of the contact matrix prior to the pandemic, and thus βi,j = P(t)Ci,j(0) with P(t) ≡ ω(t)pc.

The contact matrix can be determined from ad-hoc suppositions and by some type of fitting of incidence data in a given population [37, 38]. A more realistic estimation can be obtained from field work recording the contacts of a sample of individuals of different age groups as implemented for a few countries: eight European countries (Belgium, Germany, Finland, Great Britain, Italy, Luxembourg, The Netherlands and Poland) [47], China [39], France [40], Japan [41], Kenya [42], Russia [43], Uganda [44], Zimbabwe [45] and Hong Kong [46]. We estimate the contact matrix using the average value of contacts from Mossong et al. [47] (see additional discussion in the S1 File).

Implementing the superspreaders group

Alongside the nine age groups defined above, we introduce a tenth group, which we call here superspreaders, composed by individuals with a much higher number of social contacts than the average in the population. Those are usually economically active individuals such as personnel in retail shops, public transport workers, health care personnel and teachers, among others. As a first simpler approach, and noting that the average age of such individuals are in the thirties, we consider that 20% of the population in the age group of 30 to 39 years old (the fourth age group) as superspreaders, with the same epidemiological parameters but different number of contacts per unit of time. This percentage is of course arbitrary and certainly varies from place to place, but it is a rough approximation of the active population with jobs requiring a large number of social contacts. The new contact matrix C¯ can then be written as

C¯i,j=Ci,j,i=1,,M,i4,j=1,,M,C¯4,j=0.8C4,j,j=1,,M,C¯i,M+1=αCi,4,C¯i,M+1=αCi,4,i=1,,M,C¯M+1,M+1=αC4,4, (2)

where α is a contact factor denoting the excess in contacts with respect to the average of the 30–39 years age group. Supposing that with implemented measures for social distancing α is kept at the value α = 1 and at a later stage, mimicking a return to normal activities, it is set to a value 3 ≤ α ≤ 10.

Population per age group in Brazil is obtained from the 2010 census data [48], corrected from official estimates for the population in each Brazilian state and the Federal District and available at [48]. Current data for Portugal is available at [49]. In the present work Portugal is considered as a whole, and model parameters for Brazil are separately fitted for each of the 26 states plus the Federal District, and final results are then added to obtain a gross total for the country. COVID-19 data for Portugal was obtained from the World Health Organization Coronavirus Disease (COVID-19) Dashboard [50], and data for each Brazilian state from the Brazilian Health Ministry [51].

It is a well-known fact that the total number of cases is highly underestimated, mainly due to a limited number of tests, and that deaths by COVID-19 are more reliable, although also subject to some under-reporting [52, 53]. As a consequence, fitting the model using the data series for the number of deaths yields results closer to the real situation. The transmission matrix is then obtained by fitting the function P(t) in order to reproduce the reported time series of deaths (see S1 File).

Results

We apply the epidemiological model described in the Methods section for Brazil and Portugal. In the present work, Portugal is considered as a whole, while model free parameters for Brazil are separately fitted for each of the 26 states plus the Federal District, and final results are then added to obtain a gross total for the country. The model is calibrated by fitting the model output for the cumulative total number of new deaths. Population data for both countries is available at [48] for Brazil and [49] for Portugal. The 2010 census data for Brazil is linearly update using the current population official estimates. Data for the total number of cases and deaths by COVID-19 is available for Portugal at [20] and for Brazil at [21]. The time series used here span the period from the first COVID-19 case detected (3/1/2020 for Portugal and 2/26/2020 for Brazil) up to August, 15 for both countries and we keep the stage of transmission fitted in the model corresponding for the dates of January, 15 and January, 1st for Brazil and Portugal, respectively. These are also the dates for the beginning of the vaccination scenarios we discuss here.

As a simpler approach to model the effects of a superspreader group we consider that 20% of the age group from 30 to 39 years of age are superspreaders, which amounts to 3.2% of the total population of Brazil and 2.5% of Portugal. We also suppose that due to social distancing, superspreaders follow the same contact pattern as other individuals of the same age group, and that at a further time (March, 16 2021 for Portugal and March 6, 2021 for Brazil), they resume full contact. We consider superspreaders as having α = 3 to α = 10 times more contacts in average that the number of contacts for the 30 to 39 years group, with α called the contact factor.

The population is split in the following age groups: 0 to 9, 10 to 19, 20 to 29, 30 to 39, 40 to 49, 50 to 59, 60 to 69, 70 to 79 and 80 years or more. We consider two different vaccine efficiencies: ev = 0.7 and ev = 0.95, and the following scenarios:

  • Evolution without any vaccination;

  • Vaccination plan 1: First vaccinate individuals with 60 years of age and older, and then those from other age groups in descending order of age;

  • Vaccination plan 2: Start vaccination by superspreaders, and then follow the order as in the previous case.

We also assume that vaccines protect against the disease and avoid transmission, that full immunization is attained after 30 days of the first dose and that two doses are required. The total supposed number of doses is 20 million for Portugal and 250 million for Brazil, available in a time span of one year. The predicted number of deaths for each scenario from our epidemiological model is given in Fig 3, and the total number of cases in Fig 4. For details on the model and it is calibrated from empirical data see the Methods section and S1 File.

Fig 3. Total number of deaths obtained from the fitted epidemiological model.

Fig 3

The results are for two different vaccine efficacy scenarios for Brazil A) ev = 95%, B) ev = 70%, and for Portugal with C) ev = 95%, D) ev = 70%. Black arrows indicates the beginning of each vaccination plan while red arrows the moment when superspreaders return to full activity, with α = 3 to α = 10 times more contacts than typically for its age group (30 to 39 years old). The shaded blue area gives the prognostics in the absence of any vaccination. The green area gives the prognostics with vaccination starting with individuals aged 60 years and older and then vaccinating the remaining population in descending order of age group (vaccination plan 1). The red region corresponds to vaccination plan 2 starting with the superspreaders and then proceeding in the same order as in vaccination plan 1. Each shaded region is delimited by the evolution with contact factors α = 3 and α = 10.

Fig 4. Total number of symptomatic cases: Brazil (A) ev = 0.95, (B) ev = 0.7, and Portugal (C) ev = 0.95 and (D) ev = 0.7, for the vaccinations campaigns with superspreaders as described in the main text.

Fig 4

The black arrows indicate starting of vaccination and red arrows the moment superspreaders return to full social contact (3 ≤ α ≤ 10). The lower and upper curves defining the green and red shaded areas correspond to α = 3 and α = 10, respectively.

Healthcare demand is also estimated from hospitalized variable Hi in the model. The proportions of mild, severe and critical COVID-19 cases among symptomatic individuals are 80.9%, 13.8% and 4.7%, respectively [11], and we assume that severe and critical cases require hospitalization and that all severe cases demand ICU attention, i.e. 25.4% of the hospitalized individuals [11]. The estimated ICU demand in beds for 2021 in each hypothetical scenario, are shown in Table 2.

Table 2. Estimated demand of ICU beds for each vaccination plan and limit contact factors α = 3 and α = 10.

Plan 1 plan2
Country α e v ICU beds Country α e v ICU beds
Brazil 3 0.7 74490 Brazil 3 0.7 63339
3 0.95 66720 3 0.95 52966
10 0.7 179754 10 0.7 117786
10 0.95 162049 10 0.95 73659
Portugal 3 0.7 1990 Portugal 3 0.7 1835
3 0.95 1811 3 0.95 1619
10 0.7 2179 10 0.7 1835
10 0.95 1811 10 0.95 1619

The total number of symptomatic cases for each vaccination (and no vaccination) scenario are shown in Fig 4. By including the superspreaders in the first group to be vaccinated results in a significant reduction in the number of COVID-19 cases, which at its turn results in reduction in hospitalizations. We note that this reduction in the total number of symptomatic cases also reduces the number of individuals with long-term health effects due to COVID-19, also resulting in a reduction in health spending in each country.

Discussion

We note that starting vaccination by the superspreader group, as defined here, is only effective if their average contact number is a few times that of the average in the population. Using the estimated contact matrix, we obtained the average number of contacts of a single individual with individuals of any age group in Brazil as 15.6 per day and 13.8 per day in Portugal. This implies that the superspreader group has approximately 4 to 12 times the average number of contact in the population as obtained from the entries of the contact matrix (see S1 File), for the contact factor range of α = 3 to α = 10. From our results we observe a threshold value for the contact factor such that starting vaccination by the superspreaders followed by the eldest members of the population is more beneficial, in the sense that the death toll and the total number of cases decrease significantly if compared to vaccination starting only by the eldest, as seen in Fig 3. This also depends on the current situation of the pandemic in each location, and is more pronounced in an expanding phase. The reduction in the peak demand for ICU beds in Table 2 is also significant, an important point in order to avoid the overwhelming of health facilities.

From the contact matrix one could argue that first vaccinating those in the age group of 10 to 19 years of age, the one with the naturally highest number of contacts due to school attendance, could reduce the overall virus transmission. While this is true, the time span required would leave the eldest age group exposed to the virus, resulting in a higher overall mortality. Finally, the simpler case considered here of superspreaders being limited to the 30–39 years age group can be extended to encompass other age groups, by taking into account demographics and data on occupation distribution for each population, to obtain a more realistic estimate of the superspreader group and the most beneficial vaccination strategy.

We note that the boundaries of each simulated scenario for plan 2 (given by α = 3 and α = 10), represented by the shaded regions in red in Fig 3, have a smaller width than the one for plan 1 (in green). This implies a weaker dependency on the number of contacts of the superspreaders, which is another favorable point for first vaccinating the superspreaders group. We also considered the important issue of the expected number of ICU beds required. For the scenarios considered here it is significantly smaller if superspreaders are vaccinated first, with an the overall reduction of the number of persons requiring hospitalization for any value of contact factor considered here. These results suggest that starting vaccination by those with a a much greater number of contacts allows a greater flexibility in economic activities, due to the smaller dependent on the size of superspreaders group and their contact structure.

A more detailed study for each location using data on the economic activities, if available, is necessary to design a more efficient vaccination plan in the line discussed here, and increase the overall number of lives saved, and given the current conditions and considering the lack of basic resources for vaccination in several countries. Our results can be extended straightforwardly to other countries and show the benefits of a carefully designed vaccination strategy maximizing the results from a limited number of vaccine doses and limited infrastructure and logistics. We also note that the predicted number of hospitalized individuals correspond to an ideal setting, such that every severe or critical case will be hospitalized. This is not always the case due to limitations of available medical facilities. Therefore, a reduction of the hospitalization demand is also critically important for a reduction in the total number of deaths caused by the disease.

More than 50% of the population of both countries considered in the present study are already fully vaccinated, but the considerations here are still valid for other groups in the population such as children and adolescents who have an high number of contacts due to school attendance and are not yet fully vaccinated, mainly in Brazil. The main objective of the present study is to present a proof of concept for the importance of different vaccination strategies than those currently considered in most of the world, and draw attention to those individuals with a very high number of contacts, which are superspreaders in the sense that, beside being more prone to infection, they also function as hubs for the propagation of the virus. Using a modeling approach allows us to explore possible different scenarios and bring forward the need for a more thorough investigation into the optimal use of vaccines, particularly in those countries which are still lagging behind in the proportion of the population already fully vaccinated.

Limitations

As any model based approach, the results can only reflect what is fed into the model itself. Our approach relies on epidemiological parameters reported in the literature, which can vary for different localities and over time, e. g. the infection fatality ratio due to the overwhelming health infrastructure, partially considered for Brazil, or new variants. We also supposed that the reinfection proportion is negligible and that mixing is homogeneous, discarding heterogeneous effects in the population. The identification of superspreaders is also a difficult element of our approach, although some professional activities can be readily recognized as such, as public transport workers, health care personnel and teachers.

Supporting information

S1 File

(ZIP)

Data Availability

All relevant data are within the manuscript and its Supporting information files.

Funding Statement

This work received financial support from the National Council of Technological and Scientific 242 Development - CNPq (grant numbers 302449/2019-1 FAS, 309617/2020-0 ACGA, 243 305291/2018-1 MAM), Bahia State Research Support Foundation (BOL0723/2017 AJAC) 244 (Brazil) and i3N (grant numbers UIDB/50025/2020 & UIDP/50025/2020) - Fundação para a 245 Ciência e Tecnologia/MEC (Portugal). The funders had no role in study design, data collection 246 and analysis, decision to publish, or preparation of the manuscript.

References

  • 1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. (2020) 382, 727 (2020). doi: 10.1056/NEJMoa2001017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.World Health Organization. n.d. Novel Coronavirus (2019-NCoV) Situation Reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
  • 3.COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at John Hopkins University (JHU). https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6. Accessed August, 17 2021.
  • 4. Zhou T, Liu Q, Yang Z, et al. Preliminary prediction of the basic reproduction number of the Wuhan novel coronavirus 2019-nCoV. Journal of Evidence Based Medicine (2020) 13, 3. doi: 10.1111/jebm.12376 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Fraser C. Estimating Individual and Household Reproduction Numbers in an Emerging Epidemic. PLoS ONE (2007) 2, e758. doi: 10.1371/journal.pone.0000758 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Kwok KO, Lai F, Wei WI, et al. Herd immunity—estimating the level required to halt the COVID-19 epidemics in affected countries. Journal of Infection (2020) 80, e32. doi: 10.1016/j.jinf.2020.03.027 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Fontanet A, Cauchemez S. COVID-19 herd immunity: where are we? Nat. Rev. Immunol. (2020) 20, 583. doi: 10.1038/s41577-020-00451-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Verity R, Okell L, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: A model-based analysis. Lancet Infec. Dis. (2020) 20, 669. doi: 10.1016/S1473-3099(20)30243-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Cho S-W. Quantifying the impact of nonpharmaceutical interventions during the COVID-19 outbreak: the case of Sweden. Economet. J. (2020) 23, 323. doi: 10.1093/ectj/utaa025 [DOI] [Google Scholar]
  • 10. Sheridan A, Andersen AL, Hansen ET, Johannesen N. Social distancing laws cause only small losses of economic activity during the COVID-19 pandemic in Scandinavia. P. Natl. Acad. Sci. USA (2020) 117, 20468. doi: 10.1073/pnas.2010068117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19)—China. CCDC Weekly (2020) / Vol. 2 / No. 8. doi: 10.46234/ccdcw2020.032 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Davies NG, Barnard RC, Jarvis CI, et al. Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England. medRχiv (2020). doi: 10.1101/2020.12.24.20248822 [DOI] [Google Scholar]
  • 13. Tegally H, Wilkinson E, Giovanetti M, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv (2020). doi: 10.1101/2020.12.21.20248640 [DOI] [Google Scholar]
  • 14. Ndwandwe D., Wiysonge CS. COVID-19 vaccines. Curr. Opin. Immunol. (2021) 71, 111. doi: 10.1016/j.coi.2021.07.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.World Health Organization. Coronavirus disease (COVID-19): Vaccine access and allocation. https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-vaccine-access-and-allocation. Accessed August, 17 2021.
  • 16.Centers for Disease Control and Prevention. How CDC Is Making COVID-19 Vaccine Recommendations. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations-process.html. Accessed August, 17 2021.
  • 17.European Centre for Disease Prevention and Control. Overview of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA and the UK. https://www.ecdc.europa.eu/en/publications-data/overview-current-eu-eea-uk-plans-covid-19-vaccines. Technical report. June, 14 2021.
  • 18.Ministério da Saúde do Brasil. Plano Nacional de operacionalização da vacinação contra a COVID-19. https://www.gov.br/saude/pt-br/coronavirus/publicacoes-tecnicas/guias-e-planos/plano-nacional-de-vacinacao-covid-19/view. Accessed August, 17 2021.
  • 19. Luyten J, Tubeuf S, Kessels R. Who should get it first? Public preferences for distributing a COVID-19 vaccine. Covid. Econ. (2020) 57, 1. https://cepr.org/file/9988/download?token=NqOyq6ZR [Google Scholar]
  • 20. Kartoglu UH, Moore KL, Lloyd JS. Logistical challenges for potential SARS-CoV-2 vaccine and a call to research institutions, developers and manufacturers. Vaccine (2020) 38, 5393. doi: 10.1016/j.vaccine.2020.06.056 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Krammer F. SARS-CoV-2 vaccines in development. Nature (2020) 586, 516. doi: 10.1038/s41586-020-2798-3 [DOI] [PubMed] [Google Scholar]
  • 22. van Riel D, Wit E. Next-generation vaccine platforms for COVID-19. Nat. Mat. (2020) 19, 810. doi: 10.1038/s41563-020-0746-0 [DOI] [PubMed] [Google Scholar]
  • 23. Kabir R, Mahmud I, Chowdhury MTH, et al. COVID-19 Vaccination Intent and Willingness to Pay in Bangladesh: A Cross-Sectional Study. Vaccines (2021) 9, 416. doi: 10.3390/vaccines9050416 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Mahmud I, Kabir R, Rahman MA, et al. The Health Belief Model Predicts Intention to Receive the COVID-19 Vaccine in Saudi Arabia: Results from a Cross-Sectional SurveyVaccines (2021) 9, 864. doi: 10.3390/vaccines9080864 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Pastor-Satorras R, Vespignani A. Epidemic spreading in scale-free networks. Phys. Rev. Lett. (2001) 86, 3200. doi: 10.1103/PhysRevLett.86.3200 [DOI] [PubMed] [Google Scholar]
  • 26. Pastor-Satorras R, Vespignani A. Immunization of complex networks. Phys. Rev. E (2002) 65, 036104. doi: 10.1103/PhysRevE.65.036104 [DOI] [PubMed] [Google Scholar]
  • 27. Dezsö Z, Barabási A-L. Halting viruses in scale-free networks. Phys. Rev. E (2002) 65, 055103. doi: 10.1103/PhysRevE.65.055103 [DOI] [PubMed] [Google Scholar]
  • 28. Dorogovtsev SN, Mendes JFF. Evolution of Networks. Advances in Physics (2001) 51, 1079. doi: 10.1080/00018730110112519 [DOI] [Google Scholar]
  • 29. Dorogovtsev SN, Goltsev AV, Mendes JFF. Critical phenomena in complex networks. Rev. Mod. Phys. (2008) 80, 1275. doi: 10.1103/RevModPhys.80.1275 [DOI] [Google Scholar]
  • 30. Goltsev AV, Dorogovtsev SN, Oliveira JG, Mendes JFF. Localization and Spreading of Diseases in Complex Networks. Phys. Rev. Lett. (2012) 109, 128702. doi: 10.1103/PhysRevLett.109.128702 [DOI] [PubMed] [Google Scholar]
  • 31.DIreção Geral de Saúde de Portugal. https://covid19.min-saude.pt. Accessed August, 17 2021.
  • 32.New York Times. racking Coronavirus Vaccinations Around the World. https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html. Accessed August, 17 2021.
  • 33. Linton NM, Kobaiashi T, Yang Y, et al. Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data. J. Clin. Med. (2020) 9, 538. doi: 10.3390/jcm9020538 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann. Intern. Med. (2020) 172, 577. doi: 10.7326/M20-0504 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, Shaman J. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). Science (2020) 368, 489–493. doi: 10.1126/science.abb3221 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Russell TW, Hellewell J, Jarvis CI, et al. Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. Euro Surveill. (2020) 25, 2000256. doi: 10.2807/1560-7917.ES.2020.25.12.2000256 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Magpantay FMG, King AA, Rohani P. Age-structure and transient dynamics in epidemiological systems, J. R. Soc. Interface (2019) 16, 151. doi: 10.1098/rsif.2019.0151 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Manfredi P, Williamn JR, Ciofi Drergliatti ML, Salmaso S. Measles elimination in Italy: projected impact of the National Elimination Plan. Epidemiol. Infect. (2005) 133, 87. doi: 10.1017/s0950268804003152 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Read JM, Lesser J, Riley S, et al. Social mixing patterns in rural and urban areas of southern China. Proc. Royal Soc. London B (2014) 281, 20140268. doi: 10.1098/rspb.2014.0268 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Béraud G, Kazmercziak S, Beutels P, et al. The French connection: the first large population-based contact survey in France relevant for the spread of infectious diseases. PloS one (2015) 10, e0133203. doi: 10.1371/journal.pone.0133203 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Ibuka Y, Ohkusa Y, Sugawara T, et al. Social contacts, vaccination decisions and influenza in Japan. J. Epidemiol. Community Health (2016) 70, 162. doi: 10.1136/jech-2015-205777 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Kiti MC, Kinyanjui TM, Koech DC, Munywoki PK, Medley GF, Nokes DJ. Quantifying age-related rates of social contact using diaries in a rural coastal population of Kenya. PloS One (2014) 9, e104786. doi: 10.1371/journal.pone.0104786 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Ajelli M, Litvinova M. Estimating contact patterns relevant to the spread of infectious diseases in Russia. J. Theor. Biol. (2017) 419, 1. doi: 10.1016/j.jtbi.2017.01.041 [DOI] [PubMed] [Google Scholar]
  • 44. le Polain de Waroux O, Cohuet S, Ndazima D, et al. Characteristics Of Human Encounters And Social Mixing Patterns Relevant To Infectious Diseases Spread By Close Contact: A Survey In Southwest Uganda. BMC Infec. Dis. (2018) 18, 172 (2018). doi: 10.1186/s12879-018-3073-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Melegaro A, Del Fava E, Poletti P, et al. Social Contact Structures and Time Use Patterns in the Manicaland Province of Zimbabwe. PloS one (2017) 12, e0170459. doi: 10.1371/journal.pone.0170459 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Leung K, Jit M, Lau EH, Wu JT. Social contact patterns relevant to the spread of respiratory infectious diseases in Hong Kong. Sci. Rep. (2017) 7, 7974. doi: 10.1038/s41598-017-08241-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Mossong J, Hens M, Jit M, et al. Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases. PLOS Med. (2008) 5, e74. doi: 10.1371/journal.pmed.0050074 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Instituto Brasileiro de Geografia e Estatística (IBGE). https://brasilemsintese.ibge.gov.br/populacao/.
  • 49.Fundação Francisco Manuel dos Santos. https://www.pordata.pt/.
  • 50.World Health Organization. Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int. Accessed August, 17 2021.
  • 51.Ministério da Saúde do Brasil. Coronavírus Brasil. https://covid.saude.gov.br. Accessed August, 17 2021.
  • 52. Rahmandad H, Lim TY, Sterman J. Estimating COVID-19 under-reporting across 86 nations: implications for projections and control. (November 25, 2020). medRχ iv (2020). doi: 10.1101/2020.06.24.20139451 [DOI] [Google Scholar]
  • 53. Woolf SH, Chapman DA, Sabo RT, et al. Excess Deaths From COVID-19 and Other Causes, March-April 2020. JAMA (2020) 324, 510. doi: 10.1001/jama.2020.11787 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

M Shamim Kaiser

6 Oct 2021

PONE-D-21-27433Optimization of COVID-19 vaccination and the role of individuals with a high number of contacts: a model based approachPLOS ONE

Dear Dr. 33457670153,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

ACADEMIC EDITOR: The following major issues must be addressed: 

  • Could you justify why the particular age group was picked for the model development?

  • The authors only chose Brazil and Portugal. They are in different phases of vaccination. In sensing the full data, my first notice is that Brazil fitting into the unpredictable model is just 20.3 percent compared to Portugal. It would be amazing if the authors recognized that the vaccination stage is over 50% or more other than Brazil and Portugal.

  • I have noticed some typos and grammatical issues, thus read the article carefully.

Please submit your revised manuscript by Nov 20 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

M. Shamim Kaiser, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

3. Thank you for stating the following financial disclosure: 

"17474"

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

4. Thank you for stating the following in the Acknowledgments Section of your manuscript: 

"This work received financial support from the National Council of Technological and Scientific 222

Development - CNPq (grant numbers 302449/2019-1 FAS, 309617/2020-0 ACGA, 223

305291/2018-1 MAM), Bahia State Research Support Foundation (BOL0723/2017 AJAC) 224

(Brazil) and i3N (grant numbers UIDB/50025/2020 & UIDP/50025/2020) - Fundação para a 225

Ciência e Tecnologia/MEC (Portugal)"

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

"17474"

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

5. Please upload a copy of Figure S3, to which you refer in your text on pages 5 and 6. If the figure is no longer to be included as part of the submission please remove all reference to it within the text.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This manuscript is well written but needs correction of some important points before publication. Like in introduction need to add information from the below recent papers;

https://doi.org/10.3390/vaccines9080864

https://doi.org/10.3390/vaccines9050416

There is not enough methodological information in the abstract.

Present the methods section before the results and discussion.

Could you please justify the reasons why the specific age group was selected for the model development and what are the reasons for vaccination failure among that group.

Add more clarity around super spreaders group.

The strengths of the research are not clearly established.

Reviewer #2: The research ‘Optimization of COVID-19 vaccination and the role of individuals with a high number of contacts: a model based approach’ is interesting. It proposed a methodology to carefully analyze the current situation of Covid-19, considering the social contacts structure in a given population and its age distribution. Alongside, it deeply analyzed the vaccine efficacy, prioritizations of vaccination strategies, successful and equitable vaccination strategy and vaccine input methodology by fitting different hypothetical scenarios into a epidemiological model. Its not a big surprise that super-spreaders play the key role for transmission, infection, fatality as well as prevention of any contagious diseases like covid-19. But the way the authors use the data of super-spreaders in the model is a good one.

The authors have chosen only Brazil and Portugal as they are originated from these countries. These they are in different vaccination stages, with 20.3% and 64.75% of the population in Brazil and Portugal fully vaccinated, respectively. By sensing the whole study, my first observation is that the case of Brazil fitting in the model given unseemly results in compare with Portugal as Brazil has only 20.3%. Its troublesome to discuss future optimal vaccination campaigns for any community by model fitting only a small population like Brazil. It would be great if the authors considered another besides Brazil and Portugal where the vaccination stage is above 50% or more.

How does the authors deal with the uncertainties of the model. There are many considerations the authors considered to run the model. For example, reinfection proportion is negligible and that mixing is homogeneous, discarding heterogeneous effects in the population. Why and How?

How does the authors consider that 20% of the age group from 30 to 39 years of age are superspreaders, which amounts to 3.2% of the total population of Brazil and 2.5% of Portugal?

Different age groups (9 groups here) should have different behavioral pattern and it varies with locality and time. Why didn’t the authors use any coefficient or else to remove the uncertainties raised the by the said issues?

In a study I found that prioritizing adults aged 60+ years remained the best way to reduce mortality and YLL for R0 ≥ 1.3, but prioritizing adults aged 20 to 49 years was superior for R0 ≤ 1.2. Prioritizing adults aged 20 to 49 years minimized infections for all values of R0 investigated. How does this results connect with the results in this manuscript. If differ, why?

It would be good if the authors considered two factors more e.g. vaccines with imperfect transmission-blocking effects, incorporation of population seroprevalence and individual serological testing.

I found many works in the literature on approximately same topic. In such context, this can be considered a prototype work. But, the model extracted results offered herein this study provoked me to the favor of publishing this manuscript in Plos One. In my opinion, it needs a further review after a major revision where the authors address the above flaws.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Mar 8;17(3):e0262433. doi: 10.1371/journal.pone.0262433.r002

Author response to Decision Letter 0


19 Nov 2021

ACADEMIC EDITOR:

The following major issues must be addressed:

COMMENT: "Could you justify why the particular age group was picked for the model development?"

ANSWER: The different age groups were chose based on the available information by age group on hospitalization and death probabilities by infection. The age group for superspreaders correspond to the the "average" age group pf the economically active population, and is a simplification introduced in the model. In this way, we believe it depicts well what occurs with those individuals with a much greater number of contacts in the whole population.

COMMENT: "The authors only chose Brazil and Portugal. They are in different phases of vaccination. In sensing the full data, my first notice is that Brazil fitting into the unpredictable model is just 20.3 percent compared to Portugal. It would be amazing if the authors recognized that the vaccination stage is over 50% or more other than Brazil and Portugal."

ANSWER: We added a comment on this in the last paragraph of the Discussion section.

COMMENT: "I have noticed some typos and grammatical issues, thus read the article carefully."

ANSWER: we did it.

Journal Requirements:

We correctec the funding information in the Acknowledgments section. We added to it the phrase "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

COMMENT: "5. Please upload a copy of Figure S3, to which you refer in your text on pages 5 and 6. If the figure is no longer to be included as part of the submission please remove all reference to it within the text."

ANSWER: There is no citation to Figure S3, but to Table S3, which is included in the supplemental material.

COMMENT: "PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files."

ANSWER: Yes

Reviewers' comments:

Reviewer #1

COMMENT: "This manuscript is well written but needs correction of some important points before publication. Like in introduction need to add information from the below recent papers;

https://doi.org/10.3390/vaccines9080864

https://doi.org/10.3390/vaccines9050416"

ANSWER: We added a comment on the need to consider willingness to vaccinate and the economic cost for individuals, and cited the suggested references.

COMMENT: "There is not enough methodological information in the abstract."

ANSWER: We added some information of the methodology in the abstract

COMMENT: "Present the methods section before the results and discussion."

ANSWER: Done.

COMMENT: "Could you please justify the reasons why the specific age group was selected for the model development and what are the reasons for vaccination failure among that group.

Add more clarity around super spreaders group."

ANSWER: We explained more explicitly in the first paragraph of the subsection "Implementing the superspreaders group".

COMMENT: "The strengths of the research are not clearly established."

ANSWER: We added a paragraph in the end of the Discussions section. We believe that this will put more clearly the strength and goals of

the present work.

Reviewer #2

COMMENT: "The authors have chosen only Brazil and Portugal as they are originated from these countries. These they are in different vaccination stages, with 20.3% and 64.75% of the population in Brazil and Portugal fully vaccinated, respectively. By sensing the whole study, my first observation is that the case of Brazil fitting in the model given unseemly results in compare with Portugal as Brazil has only 20.3%. Its troublesome to discuss future optimal vaccination campaigns for any community by model fitting only a small population like Brazil. It would be great if the authors considered another besides Brazil and Portugal where the vaccination stage is above 50% or more."

ANSWER: The present work is a first study in this direction, and is a proof of concept for the need of a more detailed consideration of different possibilities for vaccination strategies. A more detailed study, with a version of the model considering different kinds of vaccine is under way, mainly for countries with a very low proportion of the population fully vaccinated and located mainly in sub-Saharan Africa. We hope that the current approach may be useful in countries where the available number of doses is still very small.

COMMENT: "How does the authors deal with the uncertainties of the model. There are many considerations the authors considered to run the model. For example, reinfection proportion is negligible and that mixing is homogeneous, discarding heterogeneous effects in the population. Why and How?"

ANSWER: As for any modeling approach, some simplifications are considered, while more important aspects are considered with more care. Heterogeneous effects may be considered in more complex models, but are also very hard to model as more information is needed. The use of homogeneous mixing, although being a simplification often used, allows to calibrate the model with available data and yet obtain important insights on the pandemic dynamics. Reinfection is expected to be not significant for the amount of time considered in the present work.

COMMENT: "How does the authors consider that 20% of the age group from 30 to 39 years of age are superspreaders, which amounts to 3.2% of the total population of Brazil and 2.5% of Portugal?"

ANSWER: We introduced some explanation on this on the first paragraph of the subsection on "Implementing the superspreaders group".

COMMENT: "Different age groups (9 groups here) should have different behavioral pattern and it varies with locality and time. Why didn’t the authors use any coefficient or else to remove the uncertainties raised the by the said issues?"

ANSWER: This is indeed true. The dependence on locality is obtained mainly by field studies such as the one in Mossong et al. Unfortunately no such study was performed for Brazil or Portugal, so we have to assume that the average number of contacts between two age-groups is the same as the average for the European countries considered by Mossong et al. This a a quite reasonable assumption as both Brazil and Portugal have mainly an European culture and most of its population live in cities, as in most Europe. Besides the contact matrix used in the model is obtained properly considering the population by age-group in each country, which results in different contact matrices. The time evolution of the contact structure is approximately taken into account by a constant factor multiplying the contact matrix that considers at the same time the increase or decrease of average contacts and probability of transmission, and fitted from real data, as explained in the text.

COMMENT: "In a study I found that prioritizing adults aged 60+ years remained the best way to reduce mortality and YLL for R0 ≥ 1.3, but prioritizing adults aged 20 to 49 years was superior for R0 ≤ 1.2. Prioritizing adults aged 20 to 49 years minimized infections for all values of R0 investigated. How does this results connect with the results in this manuscript. If differ, why?"

ANSWER: The point here is that if you have to chose only by age-group, then it starting by the group with higher age results in the most significant reduction of hospitalizations and deaths, and this is currently the most frequent strategy adopted by far. What we are drawing some attention on that there are other possibilities that may result in a more significant reduction of cases and deaths by COVID-19, i.e. by first vaccinating the superspreaders group and afterwards by following reverse chronological order of age.

COMMENT: "It would be good if the authors considered two factors more e.g. vaccines with imperfect transmission-blocking effects, incorporation of population seroprevalence and individual serological testing."

ANSWER: This was partially taken into consideration when considering vaccines with an efficiency varying from 0.7 to 0.95. A more detailed study in this direction is underway in out group.

COMMENT: "I found many works in the literature on approximately same topic. In such context, this can be considered a prototype work. But, the model extracted results offered herein this study provoked me to the favor of publishing this manuscript in Plos One. In my opinion, it needs a further review after a major revision where the authors address the above flaws."

ANSWER: We believe that the above mentioned corrections and answers satisfy this referee's comment.

Attachment

Submitted filename: rebuttal.docx

Decision Letter 1

M Shamim Kaiser

26 Dec 2021

Optimization of COVID-19 vaccination and the role of individuals with a high number of contacts: a model based approach

PONE-D-21-27433R1

Dear Dr. 33457670153,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

M. Shamim Kaiser, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Thank you for responding to all of the reviewers' concerns.

However, the paper contains a few mistakes. Please take your time reading this paper carefully.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thanks for doing all the changes as suggested. The manuscript sounds technically good and well revised.

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Acceptance letter

M Shamim Kaiser

10 Jan 2022

PONE-D-21-27433R1

Optimization of COVID-19 vaccination and the role of individuals with a high number of contacts: a model based approach

Dear Dr. 33457670153:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. M. Shamim Kaiser

Academic Editor

PLOS ONE


Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES